Did you know that 41% of oncology studies use a Data Monitoring Committee (DMC), compared to just 34% of non-oncology studies? The disparity is even more significant in phase 3 trials, where 78% of oncology studies employ a DMC, compared to 43% in non-oncology trials. Why is there such high use of DMCs in oncology studies, and what unique challenges do they address?

Join us for a comprehensive webinar where we explore the critical role of DMCs in oncology studies. This session, presented by experts David Kerr, Kent Koprowicz, and Bill Coar, will delve into the unique aspects of DMCs in oncology trials, providing valuable insights for ensuring trial integrity and patient safety.

Key topics

• Introduction to DMCs in Oncology: Understanding the evolution and importance of DMCs in oncology studies.
• FDA Guidance on DMCs: Key considerations for the use of DMCs in clinical trials.
• Unique Challenges in Oncology Studies: Addressing issues in open-label studies, multiple endpoints, and patient populations.
• Research Insights: Analysis of DMC usage trends in oncology vs. non-oncology studies.
• Best Practices: Strategies for effective DMC operation in oncology trials, including handling of data interpretation and safety assessments.

Don’t miss this opportunity to enhance your understanding of DMCs and their impact on the successful execution of oncology studies. Register now to gain insights and practical knowledge from seasoned professionals in the field.